Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ClearPoint Neuro Inc. - Common Stock (NQ:CLPT)

14.28 +0.46 (+3.33%)
Streaming Delayed Price Updated: 10:28 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ClearPoint Neuro Inc. - Common Stock

News headline image
ClearPoint Neuro Completes Acquisition of IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Third Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain
Via ACCESSWIRE
News headline image
ClearPoint Neuro Reports Third Quarter 2024 Results
Via ACCESSWIRE
News headline image
ClearPoint Neuro Announces Expanded International Clearances for Key Therapy Delivery Product; Now Totaling 34 Countries Worldwide
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA Clearance Expanding Compatibility of the ClearPoint Prism Neuro Laser Therapy System with 1.5T MRI Scanners
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024
Via ACCESSWIRE
News headline image
ClearPoint Neuro Reports Second Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports First Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
Via ACCESS Newswire
News headline image
ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism(R) to Include 1.5 T MRI
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce First Quarter 2025 Results May 13, 2025
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Full Market Release of ClearPoint Navigation Software Version 3.0 – Delivering the First End-to-End ClearPoint Navigation Solution to the Operating Room
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0
Via ACCESS Newswire
News headline image
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
From ClearPoint Neuro, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.